A Phase Ia/Ib Study of Talazoparib in Combination With Tazemetostat in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Latest Information Update: 23 May 2024
At a glance
- Drugs Talazoparib (Primary) ; Tazemetostat (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 25 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 17 Apr 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2025.
- 17 Apr 2023 Planned primary completion date changed from 30 Mar 2023 to 30 Mar 2025.